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ABSTRACT
Detection of early osteoarthritis to stabilize or reverse the damage to articular cartilage would improve patient function, reduce disability,
and limit the need for joint replacement. In this study, we investigated nondestructive photon-processing spectral computed tomography
(CT) for the quantitative measurement of the glycosaminoglycan (GAG) content compared to destructive histological and biochemical assay
techniques in normal and osteoarthritic tissues. Cartilage-bone cores from healthy bovine stifles were incubated in 50% ioxaglate
(HexabrixV
R
) or 100% gadobenate dimeglumine (MultiHanceV
R
). A photon-processing spectral CT (MARS) scanner with a CdTe-Medipix3RX
detector imaged samples. Calibration phantoms of ioxaglate and gadobenate dimeglumine were used to determine iodine and gadolinium
concentrations from photon-processing spectral CT images to correlate with the GAG content measured using a dimethylmethylene blue
assay. The zonal distribution of GAG was compared between photon-processing spectral CT images and histological sections. Furthermore,
discrimination and quantification of GAG in osteoarthritic human tibial plateau tissue using the same contrast agents were demonstrated.
Contrast agent concentrations were inversely related to the GAG content. The GAG concentration increased from 25lg/ml (85mg/ml iodine
or 43mg/ml gadolinium) in the superficial layer to 75lg/ml (65mg/ml iodine or 37mg/ml gadolinium) in the deep layer of healthy bovine
cartilage. Deep zone articular cartilage could be distinguished from subchondral bone by utilizing the material decomposition technique.
Photon-processing spectral CT images correlated with histological sections in healthy and osteoarthritic tissues. Post-imaging material





while differentiating the underlying subchondral bone.
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INTRODUCTION
Osteoarthritis (OA) is a common cause of disability and the most
common indication for both knee and hip joint replacements.1
Theoretically, treating OA by stabilizing or reversing the articular car-
tilage damage would reduce pain and improve patient function, poten-
tially negating the need for joint replacements and, thus, reducing the
burgeoning social and economic cost of joint replacements in an ever-
aging population that increasingly expects greater levels of physical
activity and mobility.2–5
Cost-effective noninvasive methods for evaluating tissue quality
and regeneration following articular cartilage treatments are not yet
available. The existing clinical diagnostic methods have difficulty in
detecting early osteoarthritic changes and cartilage lesions.6 Clinical
assessment of OA is indirect, relying on symptoms and signs of stiff-
ness, pain, swelling, and muscle weakness. Imaging of joints with plain
x-ray to assess joint space narrowing, the appearance of subchondral
bone sclerosis, and the presence of osteophytes is cheap and simple
but unsuitable for early diagnosis as the cartilage is not imaged
directly.7–9 Magnetic resonance imaging (MRI) and computed tomog-
raphy (CT) imaging showed early promise for detection of OA and
assessment of cartilage treatments but have proven to be limited in res-
olution or quantitative capability for detecting early OA.10,11 Thus,
quantitative imaging of an in situ biomarker of cartilage health
remains the most desirable strategy.12
Sulfated glycosaminoglycans (sGAG or GAG) are sensitive bio-
markers of early cartilage degradation.13 Healthy articular cartilage con-
sists largely of an extracellular matrix containing chondrocytes with
water (65–80%), collagens (10–20%), and proteoglycans (10–20%) and
can be organized into superficial, mid, and deep zones (Fig. 1).7,14
Proteoglycans contain negatively charged GAGs, which form
non-covalent interactions with water contributing to the compressive
stiffness and lubrication between cartilage surfaces.15 The density and
sulfation of GAG are highest in the deep zone and decrease in the
more superficial layers (Fig. 1), causing a gradient in the negative fixed
charge density of the cartilage.16 The integrity and physical properties
of the articular cartilage are mainly regulated by specialized cartilage
cells, the chondrocytes.17,18 It is thought that the chondrocytes fail to
maintain healthy cartilage in OA due to multifactorial influences
including biomechanical, biochemical, and immunological events.19,20
The exact etiology of OA remains unknown despite several risk
factors having been identified.19,21,22 What is known is that the GAG
content of articular cartilage reduces following damage and increases
after successful repair and regeneration.23–25 GAG can be evaluated
via histological methods, using Safranin-O or Toluidine blue staining,
or measured by biochemical methods such as the dimethylmethylene
blue (DMMB) assay.18,25,26 While both histological and biochemical
assay techniques represent the gold standard for effective detection,
histological scoring, and quantitative assessment of GAG and tissue
quality, they are, nonetheless, destructive and invasive, requiring the
harvesting of a biopsy of cartilage tissue from the joint. For this reason,
minimally invasive MRI and CT imaging techniques have been devel-
oped for semi-quantitative assessment of the GAG content in both
clinical and research settings.27–29 For example, previous noninvasive
imaging techniques have exploited the negative charge exhibited by
GAGs by using anionic contrast agents based on iodine (I) or
gadolinium(Gd).29–36 These negatively charged contrast agents (ioxa-
glate containing iodine for CT and gadobenate dimeglumine (Gd-
BOPTA) containing gadolinium for MRI) are introduced either
directly (intra-articular) or systemically (intravenous). The negatively
charged GAG subsequently displaces the negatively charged contrast
agent, resulting in regions where the high signal or attenuation of the
contrast agent reflects regions of low GAG concentration and vice
versa. Consequently, this inverse relationship between the contrast
agent and the GAG content offers the potential to nondestructively
image changes in the GAG concentration evident in early OA by
detecting differences in the uptake of a charged contrast agent.
Anionic ioxaglate (HexabrixV
R
320, Guerbet, France), an iodine-
based contrast agent, is useful as an inverse indicator for GAG used in
CT. The micro-CT (lCT) technique is known as Equilibrium
Partitioning of an Ionic Contrast agent (EPIC) lCT.37–40 EPIC-lCT
has demonstrated imaging of GAG distribution; however, it cannot
discriminate between materials of similar x-ray attenuation. For exam-
ple, in OA, the articular cartilage adjacent to the bone may be depleted
of GAG and, therefore, exhibits high concentrations and attenuation
of the anionic contrast agent, and EPIC-lCT has difficulty in distin-
guishing the two. Since changes in the subchondral bone are another
marker of OA, it is highly desirable to measure levels of GAG and the
features of the adjacent subchondral bone concurrently.41–43
An alternative imaging modality, Delayed Gadolinium-Enhanced
MRI of Cartilage (dGEMRIC), uses MRI to measure the relaxation of
hydrogen atoms in cartilage bathed in a paramagnetic gadolinium
contrast agent, for example, gadobenate dimeglumine (MultiHanceV
R
,
Bracco, USA).29 This imaging technique is sensitive for cartilage degra-
dation, but is costly, does not have sufficiently high spatial resolution
to assess thin layers of cartilage, and has poor visualization of subchon-
dral bone features.7,37 Furthermore, there remain conflicting evidence
for its value in early OA and doubts that it correlates well with clinical
measures of cartilage repair.44,45
MARS Photon-processing spectral CT has been shown to dis-
criminate between two highly attenuating materials based on their
FIG. 1. Schematic overview of healthy articular cartilage showing the distributions
and zonal organization of collagen and chondrocytes, as well as gradients in GAG,
Collagen I, and Collagen II content via histology (Safranin-O) and immunohistology
(Coll II, Coll I) staining.
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spectral signatures in other applications.32,46 Photon-processing spec-
tral CT uses a photon-counting detector to discriminate and quantify
multiple materials simultaneously, which is not possible using the
energy-integrating detectors found in EPIC-lCT or conventional full
body clinical CT.30,34 MARS photon-processing spectral CT analyzes
the energy-dependent characteristic x-ray spectra of different materi-
als, to create a ‘color’ image of the object of interest, which we have
previously shown can provide both structural and material-related
information in the same image.32,34,35
In this study, we aimed to demonstrate that photon-processing
spectral CT imaging could spatially locate and quantify the GAG content
using multiple commonly used contrast agents (through an inverse rela-
tionship with ioxaglate and/or gadobenate dimeglumine), yet clearly
differentiates cartilage from bone. We sought to test this aim via the sys-
tematic investigation of quantitative photon-processing spectral CT
imaging of GAG distribution in healthy bovine tissue with both iodine-
and gadolinium-based contrast agents validated against quantitative
biochemical analysis (DMMB assay) of the GAG content as well as his-
tological (Safranin-O) assessment. Furthermore, as proof of concept for
nondestructive clinical imaging of GAG distribution and quantitative
assessment of cartilage health and bone architecture, we investigated
photon-processing spectral CT of osteoarthritic human tibial plateau
samples from patients undergoing total joint arthroplasty.14,29,36,40
RESULTS
Measurement of GAG in healthy cartilage
Ioxaglate and gadobenate dimeglumine reached (near) diffusion
equilibrium within 24 h as no statistical difference was found between
the 24 h and 48 h measurements of both iodine and gadolinium
concentrations, with respective p-values of 0.710 and 0.957. MARS
material maps of cartilage-bone cores incubated in ioxaglate and
gadobenate dimeglumine exhibited a gradient of attenuation through
the cartilage. The cartilage surface was highly attenuating, with
decreasing attenuation until the bone was reached. Alternatively, carti-
lage on cores without the contrast agent was much less visible with no
attenuation difference seen through the cartilage. The expected gradi-
ent in the GAG concentration was confirmed with histology showing
GAG concentrations, red color from Safranin O staining, low near the
top, and high near the bottom. Therefore, an inverse relationship
between attenuation and GAG distribution could be identified in the
MARS images of the samples (Fig. 2). In both cases, with and without
the contrast agent, the bone was highly attenuating and bone porosity
was visible. The material decomposition images of the cartilage-bone
cores illustrate a clear distinction between iodine/gadolinium within
the cartilage (false colored with the heat map) and calcium in the
underlying bone.
The concentration of iodine and gadolinium in the cartilage was
determined by measuring the attenuation from MARS images and fit-
ting this value to an attenuation-concentration curve, based on known
calibration phantom values. The concentrations of iodine and gadolin-
ium had an inverse relationship to the biochemical measure of GAG
using DMMB assay. The connection between the measured attenua-
tion, concentration of iodine or gadolinium, and GAG concentration
allowed for the determination of GAG in the cartilage based on the
measured iodine/gadolinium concentration in MARS images. Both
iodine and gadolinium concentrations had a linear relationship to
attenuation. MARS imaging measured an average iodine concentra-
tion of 85mg/ml corresponding to an average GAG concentration of
FIG. 2. (a) Histological staining (Safranin O/hematoxylin/fast green) of GAG distribution in full thickness healthy bovine cartilage (scale bar¼ 200 lm). (b) Cartilage region in
the cartilage-bone core not incubated in the contrast agent is hardly visible and no gradient can be observed; however, bone is highly attenuating. (c) and (f) Reconstructed
image of the cartilage-bone core scanned with MARS following incubation in ioxaglate or gadobenate dimeglumine, respectively. Concurrently imaged calibration tubes with
varying concentrations of iodine, gadolinium, and calcium are included below the sample image. (d) and (g) False-color materially decomposed MARS image of the same sam-
ple and corresponding calibration tubes, in panels (c) and (f), with iodine and gadolinium represented in green and calcium shown in red. (e) and (h) 3D rendering including
the sample composition with calcium in white and iodine or gadolinium in yellow. The sample is 8 mm in diameter.
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25lg/ml from DMMB assay samples in the cartilage superficial layer.
For deep layer quantification, MARS imaging measured an average
iodine concentration of 65mg/ml corresponding to an average GAG
concentration of 75lg/ml from DMMB assay samples. MARS imag-
ing measured an average gadolinium concentration of 43mg/ml corre-
sponding to an average GAG concentration of 30lg/ml from
DMMB assay samples in the superficial layer. In the cartilage deep
layer, MARS imaging measured an average gadolinium concentration
of 37mg/ml corresponding to the average GAG concentration of
75lg/ml from DMMB assay samples (Fig. 3). Quantitative biochemi-
cal data of GAG measured by destructive sampling and DMMB assay
and quantitative MARS imaging data of the iodine concentration com-
paring superficial and deep layers of the articular cartilage support
these observations, with significantly higher (p< 0.05) levels of iodine
content in superficial cartilage and a significantly greater quantity of
GAG in the deep zone (p< 0.05). This matches the expected distribu-
tion of GAG in healthy bovine articular cartilage and was also
observed in the histological sections.54 Likewise, similar results were
seen in cores with gadolinium concentrations. The GAG content for
these cores showed an overall increase with the increasing depth; how-
ever, GAG concentrations in superficial and middle layers were not
statistically significantly different (p¼ 0.14).
Comparison of the two contrast agents (ioxaglate and gadobenate
dimeglumine) in healthy bovine tissue (Fig. 4) demonstrated that the
profile of uptake through the depth of the cartilage was similar for
both contrast agents. The similar uptake in concentrations of ioxaglate
(iodine) and gadobenate dimeglumine (gadolinium) in the same sam-
ple indicates that both agents are sensitive to the GAG gradient
observed in cartilage and are able to measure similar concentrations of
GAG. No difference was observed based on the order of incubation.
Photon-processing spectral CT imaging
of osteoarthritic cartilage
In sections of OA samples not completely denuded of cartilage,
some GAG was still visible in the residual articular cartilage; however,
these samples had a significantly different appearance based on the
distribution of contrast agents from healthy cartilage. The MARS
material-decomposed images (Fig. 5) again showed an inverse correla-
tion between iodine [Fig. 5(d)] and gadolinium contrast [Fig. 5(g)]
with the GAG content observed in histological images [Fig. 5(a)], with
FIG. 3. (a) Average concentration of the GAG content in cartilage (n¼ 4) increases with the depth into the deep zone cartilage. (b) Concentration of iodine at different depths
in healthy bovine cartilage (n¼ 4) as measured by MARS decreases with the increasing depth into the cartilage. (c) GAG plotted against iodine concentrations illustrating an
inverse relationship. (d) Average concentration of GAG in the cartilage (n¼ 4) for a separate set of samples from a second stifle joint (e) Concentration of gadolinium at differ-
ent depths in healthy bovine cartilage (n¼ 4) as measured by MARS decreases with the increasing depth into the cartilage. (f) GAG plotted against gadolinium concentrations
illustrating an inverse relationship. Data are presented as mean 6 SE;  indicates p< 0.001.
FIG. 4. Measurement of iodine and gadolinium concentrations throughout the thick-
ness of cartilage, approximately 800 lm (from superficial (0%) to the deep zone
(100%)), in the same sample of healthy tissue based on attenuation of the known
concentration in calibration phantoms. Data are presented as mean 6 SD.
APL Bioengineering ARTICLE scitation.org/journal/apb
APL Bioeng. 5, 026101 (2021); doi: 10.1063/5.0035312 5, 026101-4
VC Author(s) 2021
high attenuation in the superficial zones of the cartilage where the his-
tological images displayed reduced GAG staining. In regions of
severely degenerated cartilage, there was a lack of GAG throughout
the majority of thickness of the cartilage, in addition to morphological
changes in the tissue. Material decomposition was able to separately
identify the contrast agent (iodine or gadolinium) and the calcium pre-
sent in subchondral bone. In the lateral tibial plateau, even when
increased concentrations of highly attenuating contrast agent are pre-
sent directly adjacent to the bone, a clear distinction could be observed
between cartilage and bone.
DISCUSSION
This study analyzed whether photon-processing spectral CT can
spatially locate and quantify the GAG content in healthy articular car-
tilage and osteoarthritic human articular cartilage using iodine- and
gadolinium-based contrast agents, validated against destructive bio-
chemical assay and histological techniques. There are five key findings
in this study. First, photon-processing spectral CT can accurately
determine iodine and gadolinium levels in articular cartilage incubated
in ioxaglate and gadobenate dimeglumine. Second, from quantification
using MARS imaging, anionic iodine and gadolinium concentrations
have a strong inverse relationship to the GAG content. Third, nonde-
structive photon-processing spectral CT with ioxaglate or gadobenate
dimeglumine correlates strongly with histological images of cartilage
stained for GAG. Fourth, photon-processing spectral CT can distin-
guish healthy articular cartilage high in GAG content from unhealthy
cartilage low in GAG content. Finally, ioxaglate or gadobenate dime-
glumine in the deep zone articular cartilage can be easily distinguished
from subchondral bone exhibiting similar attenuation levels.
These results suggest that photon-processing spectral CT offers
significant clinical applicability in the future as a nondestructive,
single-imaging modality for determining the health of multiple tissue
types. This is particularly relevant considering that the most direct
method to currently measure cartilage quality is to obtain histological
specimens with biochemical assays, which is destructive and
invasive to patients as well as risking further tissue degeneration and
morbidity from biopsy harvest. Nondestructive imaging modalities
are, therefore, preferred, but noninvasive assessment of cartilage
FIG. 5. (a) Histological image of a lateral human tibial plateau, stained with Safranin O/fast green/hematoxylin. Red color from Safranin O stain indicates the presence of GAG.
(b) Iodine phantom (1: 160mg/ml I; 2: 96mg/ml I; 3: 32 mg/ml I; 4: 700 mg/ml CaCl2; 5: 500 mg/ml CaCl2; 6: 15mg/ml CaCl2; 7: Oil; 8: water). (c) Single-energy image (to
mimic a conventional CT image) slice of the sample incubated in ioxaglate. (d) Material-decomposed MARS image obtained from the same sample shown in panel A. The
image shows the concentration of iodine from the anionic contrast agent (shown in the heat map as per bar on right). Calcium is shown on the grayscale. (E) Gadolinium (Gd)
phantom (1: 79mg/ml Gd; 2: 47.4 mg/ml Gd; 3: 15.8 mg/ml Gd; 4: 700 mg/ml CaCl2; 5: 500 mg/ml CaCl2; 6: 15 mg/ml CaCl2; 7: Oil; 8: water). (f) Single-energy image (to mimic
a conventional CT image) slice of the sample incubated in gadobenate dimeglumine. (g) Material-decomposed MARS image obtained from the sample shown in panel A.
The image shows the concentration of gadolinium from the anionic contrast agent (shown in the heat map as per bar on right). Calcium is shown on the grayscale. Scale bars
indicate 5mm. Note: purple layer on the top articulating surface of cartilage (d) and (g), indicating the low Gd (high GAG) concentration, is an imaging artifact due to the partial
volume effect.
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remains challenging.54 To date, MRI has provided the best soft tissue
contrast, but has a lower spatial resolution than CT. Furthermore, CT
is available to nearly all patients, whereas MRI has several contraindi-
cations and is not available to most patients with metallic implants.55
In contrast, photon-processing spectral CT provides high resolution
three-dimensional (3D) images where different materials can be iden-
tified and quantified. Our results demonstrated that photon-
processing spectral CT can accurately and simultaneously assess zonal
GAG distribution in cartilage using multiple contrast agents,
HexabrixV
R
(for CT) and MultiHanceV
R
(for MRI), as well as identify
and separate calcium in underlying bone for assessment of both carti-
lage and bone health.
Of particular interest are the material decomposition images of
the bone-cartilage explants, which demonstrated a clear distinction
between the cartilage and the underlying bone (Fig. 2). This distinction
contrasts other imaging modalities, including EPIC-lCT, where the
highly attenuating ioxaglate in the deep cartilage is often difficult to
distinguish from the highly attenuating subchondral bone.37 As EPIC-
lCT relies on attenuation differences to distinguish iodinated contrast
from bone, a reduced concentration of ioxaglate is selected for EPIC-
lCT to ensure that the cartilage can be distinguished from bone.38
Our results demonstrate that using MARS imaging allows for a clear
distinction between bone and cartilage to be identified.
The separation of bone and cartilage has also been addressed in
other studies by the development of cationic contrast agents used
alone or in combination with low concentrations of iodine-based con-
trast agents.15,56 Cationic contrast agents have a direct relationship to
the GAG content and allow clearer visual separation from subchondral
bone. Utilizing a combination of agents with different diffusion driving
forces has been theorized as a more sensitive technique for quantifica-
tion of the GAG content. However, when cartilage health is degraded
and the GAG content is low, the sensitivity of cationic agents
decreases.57,58 This is of particular importance in the superficial layer
for healthy cartilage where the low GAG concentration and/or low
GAG sulfation (i.e., low fixed charge density) is not as sensitive to the
inverse relationship demonstrated in this study as with cationic
agents.16 However, the ability to distinguish iodine, gadolinium, and
calcium using photon-processing spectral CT means that ioxaglate
and gadopentetate dimeglumine concentrations can be selected to
maximize the sensitivity of the measurement, rather than being con-
strained by the need to differentiate the contrast agent from bone.
Furthermore, using a higher concentration of contrast agent with
photon-processing spectral CT will provide increased sensitivity of
GAG quantification.
Clinical translation and validation of cationic, dual contrast
imaging, and photon-processing spectral CT for OA evaluation are
under investigation.59,60 For clinical translation of photon-
processing spectral CT, it is recognized that incubation periods of
24h utilized in this study are not practical and optimization of
in vivo incubation times, concentrations, and delivery is needed.59
Shorter incubation times, necessary for clinical use, would not sig-
nificantly affect attenuation characteristics and material decompo-
sition as a similar uptake in the tissue would be expected with a
majority of diffusion occurring initially.11 An additional challenge
in translation noted in this study was the partial volume effect.
However, this effect has been shown to be reduced when samples
are imaged in liquid and, thus, will be reduced when translated to
in vivo imaging with the presence of synovial fluid, while present-
ing the new challenge of separation of the superficial layer of carti-
lage from the contrast agent in the knee capsule. Another point in
clinical translation for photon-processing CT is that imaging of
both iodine and gadolinium based contrast agents with the same
modality is suitable for clinical use as patients with varying condi-
tions (i.e., kidney disease, allergic reactions to certain agents. etc.)
would be able to undergo imaging and assessment with the same
resolution, radiation exposure, and information obtained.60
Overall, the ability to distinguish both tissues using photon-
processing spectral CT provides a foundation for future work in
quantitative 3D assessment of both cartilage and bone health and
OA progression from a single scan (Fig. 6).
The volume of research into the diagnosis and management of
early OA continues to mount.61,62 Despite the lack of successful long-
term treatments or regenerative strategies available clinically to arrest
or reverse early OA,54,63 the need for accurate, nondestructive and
FIG. 6. Cross-sectional 3D rendering of osteoarthritic human tibial plateau incubated in the gadolinium (50% MultiHanceVR ) contrast agent. Cartilage quality is quantified based
on the GAG content validated from biochemical analysis (see the heat map) as well as 3D GAG distribution (medial-lateral; posterior-anterior), whereas bone quality is
assessed based on 3D structural properties and density, all within the single imaging modality. The GAG content shown here is based on linear relationships determined in
Fig. 3 for gadolinium. The reduced GAG content (yellow/orange) and sclerotic bone (arrow) are key factors of OA progression. Note: the purple layer on the top articulating sur-
face of cartilage, indicating the low Gd (high GAG) concentration, is an imaging artifact due to the partial volume effect.
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quantitative imaging technologies to rapidly diagnose and assess tissue
health continues to accelerate.64–67 Photon-processing spectral CT
imaging, therefore, offers the researcher or clinician the capacity to
monitor early onset OA and/or the articular cartilage response to new
OA treatments,62 as well as study the progression of tissue-engineered
cartilage or bone repair tissues in vivo over time in human or pre-
clinical animal models. One of the key outcomes of this study was vali-
dation of photon-processing spectral CT and associated material
decomposition of the gadolinium contrast agent as a single imaging
modality to quantify the GAG concentration in lg/ml throughout full
thickness cartilage (Fig. 6) relative to destructive biochemical assay
(DMMB) of the GAG content, as well as provide 3D structural infor-
mation on subchondral bone. This combination of detection of GAG
depletion, an early biomarker of OA, as well as subchondral bone
changes provides a quantitative overview of joint changes as a whole.
It is important to note that human tibial plateaus examined in this
study harvested following TKA had visual signs of early OA on the lat-
eral side. However, further investigation is needed and under way to
validate the ability of photon-processing spectral CTs to distinguish
healthy, early, and late OA in both cartilage and bone. Detection and
quantification of changes in subchondral bone (e.g., evidence of sclero-
sis or osteochondritis dissecans) especially in combination with the
reduced GAG content are key factors for identification of OA progres-
sion and diagnosis of early onset OA. The ability of photon-processing
CT to quantitatively measure cartilage and bone composition and
morphology at a high resolution is ideal for OA detection and allows
imaging of joint changes and overall joint homeostasis.
One of the limitations of this study is related to photon-
processing spectral CT outcomes on human tissue explants post-TKA
surgery for comparison with existing human clinical imaging.
However, we believe that this study demonstrates a proof of concept
and we are currently undertaking a larger study to investigate clinical
MRI and photon-processing spectral CT in an OA patient cohort.
Another limitation is the use of bovine cartilage as a surrogate for
healthy human cartilage. This tissue was selected to be used because of
the challenges in acquiring sufficient healthy human articular cartilage
tissue. Importantly, due to its similar thickness to human articular car-
tilage (approximately 2–3mm68–70), bovine articular cartilage tissue
was selected in order to optimize imaging parameters and validate the
contrast agent diffusion and biochemical GAG content, for direct
translation to human photon-processing spectral CT studies.71 The
scans were performed in the human energy range, using a spectral
detector platform being scaled to meet human scanning needs.72
Furthermore, evidence for clinical translation pathways and contrast
agent delivery includes recently established methods for intra-articular
injection of gadoterate meglumine (Gd-DOTA; DotaremV
R
, Guerbet,
France) in a pig OA model62 and current methods for administering
gadolinium contrast agents clinically via intravenous injections
adopted for dGEMRIC.6 We believe that these barriers to clinical
translation can be overcome and spectral imaging methods have sig-
nificant potential to image and quantify cartilage and bone health.
CONCLUSIONS
MARS photon-processing spectral CT imaging can quantitatively
determine the quality of both healthy and osteoarthritic articular tis-
sue. Zonal articular cartilage health from MARS imaging correlated
with destructive histological examination and quantitative biochemical
GAG assays of articular cartilage, including accurately determining the
GAG content present in full-thickness cartilage layers. Statistically sig-
nificant differences were observed in the GAG content in zonal layers
of the cartilage, which had an inverse relationship with both iodine-
and gadolinium-based contrast agent concentrations present in nor-
mal tissue. Furthermore, photon-processing spectral CT provides a
high-resolution, nondestructive method for quantification of GAG in
healthy and OA human cartilage explants and is able to distinguish
two adjacent high-contrast materials based on their spectral signatures,
enabling a clear distinction between identification of contrast agents
absorbed by cartilage and bone.
METHODS
Healthy cartilage: Sample preparation
Cylindrical healthy cartilage-bone cores (8mm diameter; n¼ 42
total) were obtained using a core drill from the femoral condylar sur-
face of bovine stifle joints. Cartilage bore cores collected for direct
comparison of biochemical (n ¼8) and histological (n¼ 8) evaluation
with contrast enhanced MARS imaging (n¼ 8) were taken adjacent to
each other on the same stifle joint. Cartilage-bone cores without the
contrast agent (n¼ 4) were used as negative controls. A separate set of
samples (n¼ 14) was used for the MARS imaging assessment of





in the same sample. All samples imaged using MARS
were fixed in 10% formalin for 48 h, which has been shown to have no
significant effect on the GAG concentration.40 While it has been noted
that formalin fixation may reduce cartilage attenuation with lCT, this
result was not observed in preliminary work with photon-processing
spectral CT.47 All samples for histology and biochemical analysis only
included the cartilage, which were sharply dissected from the bone.
Samples for histological analysis were fixed in 10% formalin for 48 h
and subsequently paraffin embedded and sectioned into 4lm slices.
For biochemical analysis, the cartilage was core biopsied with a punch
(7.80mm diameter). The samples were then frozen in the Optimal
Cutting Temperature mounting media compound (VWR, East
Grinstead, UK), and serial sections were cut from the articular surface
to the deep zone of the cartilage using a Leica CM1510 Cryostat
Microtome (Leica Biosystems, Nussloch, Germany) at 20 C. Sections
from each core were pooled to obtain samples for each of the zones
defined as superficial: 0–100lm, middle: 100–200lm, and deep:
200–600lm.48
Incubation parameters
The incubation solutions consisted of phosphate buffered saline
(PBS), protease inhibitors (Sigma-Aldrich P2714, 1X stock concentra-




concentration of 80mg I/ml (50% HexabrixV
R þ 50% PBS) was used
for iodine incubation (n¼ 4). A concentration of 79mg Gd/ml (100%
MultiHanceV
R
) was used for gadolinium incubation (n¼ 4).
Concentrations of contrast agents were based on previous experiments
described by Rajendran et al.35 Incubation was performed at 37 C
under continuous rotation with the sample fully submerged in solu-
tion. The time required to reach diffusion equilibrium of contrast
agents was investigated for HexabrixV
R
(n¼ 4) and MultiHanceVR
(n¼ 4) by performing scans after 24 h and 48 h of incubation.
Distribution of both agents in the same sample was investigated with
24 h incubation in the first agent, a 24 h washout period, 24 h
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incubation in the second agent, and a 24 h washout period. Order of
incubation was accounted for by using HexabrixV
R
first (n¼ 3) for one
group and MultiHanceV
R
first (n¼ 3) for another. Prior to MARS
imaging, the samples were rinsed with PBS for 30 s to rinse excess con-
trast agent from porous bone regions.
Photon-processing spectral CT data acquisition and
image processing
Cartilage-bone cores were placed inside a tube, along with PBS-
soaked cotton wool to provide a humidified environment during scan-
ning. A MARS-CT scanner (MARS Bioimaging Ltd, Christchurch,
New Zealand) equipped with a 2mm CdTe-Medipix3RX camera with
a pixel size of 110lm was used to scan the samples. The settings are
outlined in Table I.
Calibration tubes containing known concentrations of potassium
iodide (KI: 15, 40, 80, and 120mg/ml), gadobenate dimeglumine (Gd:
15.8, 47.4, and 79.0mg/ml), and calcium chloride (CaCl2: 15, 500, 600,
and 700mg/ml) were used as references to quantify iodine, gadolin-
ium, and calcium contents in the cores using MARS imaging.
The raw data from the specimen scans were reconstructed using
MARS Bioimaging’s iterative reconstruction algorithm.49 ImageJ soft-
ware (National Institutes of Health, USA) was used to measure the lin-
ear attenuation coefficients due to iodine and gadolinium. Regions of
interest (ROIs) were selected for the three zones of the cartilage (super-
ficial: top 100lm; middle: 100–200lm; deep: 200–600lm), which
corresponded to the histological and biochemical results. Image arti-
fact, most notably the partial volume effect, was accounted for in ROI
selection by starting one voxel below the superficial articulating surface
of the cartilage. The spectral profiles (energy-dependent X-ray attenua-
tion profiles) of the different materials in the calibration tubes were
used to spatially identify iodine, gadolinium, and calcium in the
cartilage-bone samples, using the material decomposition technique
described by Batemen and colleagues.50
For diffusion equilibrium and uptake in the same sample analy-
sis, after material decomposition was completed, the concentration of
the contrast agent was measured perpendicular on the cartilage surface
from the subchondral bone to the superficial cartilage layer across
>70% of the total cartilage volume. The average concentrations of the
plugs at 24 h and 4 8h were compared. Additionally, the average
iodine concentration at 24 h was compared with the average gado-
linium concentration at 24 h. For both comparisons, ANOVA was
used as a statistical method with a selected significance threshold
of p< 0.05.
Histology
Following fixation, dehydration, and paraffin embedding and sec-
tioning, the samples were stained with 0.1% w/v Safranin-O (Sigma-
Aldrich, India), 0.001% Fast Green FCF solution (Sigma-Aldrich, UK),
and Gill’s hematoxlin (Merck, USA) for GAG identification. These
samples were imaged using a Carl Zeiss Axio Imager 2 microscope
(Carl Zeiss Microscopy, Germany) at 5 and 10magnification.
Biochemical GAG measurement
To quantify the content of GAG in the samples, the reaction of
GAG with dimethylmethylene (DMMB) blue was measured. This
technique relies on the absorption spectra of the change in 1,9-dime-
thylmethylene dye due to the induction of metachromasia when it
binds to sulfated GAGs.51
Frozen cartilage sections were digested overnight at 56 C in
500ll 1mg/ml proteinase-K solution in digestion buffer (Tris/EDTA
buffer). Dimethylmethylene blue chloride (16lg/ml dimethylmethy-
lene blue) (Sigma-Aldrich, USA) in a solution of 3.04mg/ml glycine
and 2.37mg/ml NaCl dissolved in 0.01M HCl in d2H2O (pH 3) was
added directly followed by the measurement of the absorbance at
520 nm using a Varioskan Flash Multimode Reader (Thermo
Scientific). Chondroitin sulphate-B (Sigma-Aldrich, USA) was used to
generate a standard curve, and GAG measurements were normalized
to the wet weight.52 An ANOVA with a selected significance threshold
of p< 0.05 was used to determine statistically significant differences
between the GAG content for each layer of cartilage.
Human osteoarthritic cartilage: Sample preparation
Ethical approval was obtained from the New Zealand Health and
Disability Ethics Committee (URB/07/04/014). Written informed con-
sent was obtained from all subjects (patients, n¼ 1) in this study.
Intact tibial plateau samples were obtained during total knee arthro-
plasty (TKA) surgery following consent and stored for 3 h in PBS.
25mm strips containing both the articular cartilage and underlying
subchondral bone were cut from the central region of the plateau,
encompassing the medial and lateral tibial plateaus. These were then
separated into their medial and lateral components and frozen in PBS
at 20 C until the time of use, followed by a slow thawing process to
room temperature in order to preserve cartilage integrity.53
Photon-processing spectral CT data acquisition and
image processing
The lateral sample from the tibial plateau was thawed and then
incubated in iodine incubation solution at 37 C with constant rotation
for 24 h prior to scanning. Calibration tubes with known concentra-
tions of ioxaglate (32, 96, and 128mg/ml iodine), CaCl2 (15, 500, and
700mg/ml), water, and oil were scanned after the sample scan.
Immediately following the scan, the sample was placed into PBS for
24 h to allow the contrast agent to fully diffuse out of the tissue. After
24 h, the lateral sample of the tibial plateau was incubated in
TABLE I. MARS photon-processing spectral CT imaging protocol for healthy carti-
lage. Different energy bins were used for iodine (HexabrixVR ) and gadolinium
(MultiHanceV
R
) for identification of the element K-edge. Scans were performed using












Tube current 80lA 30 lA
Exposure time 70ms 130ms
Source object distance 166.2mm 160mm
Object detector distance 84mm 100mm
Energy bins (N) 4 4
Energy thresholds (keV) 20, 28, 35, 40 27, 33, 49, 60
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gadolinium incubation solution at 37 C with constant rotation for 24
h before scanning. Calibration tubes with known concentrations of
gadobenate dimeglumine (15.8, 47.4, and 79.0mg/ml gadolinium),
CaCl2 (15, 500, and 700mg/ml), water, and oil were scanned immedi-
ately after the sample scan.
The specimens were scanned using the same MARS spectral CT
scanner described earlier. Scan details are outlined in Table II. After
the scan, data were reconstructed using an iterative reconstruction
algorithm and material decomposition was completed as described
above.49 After material decomposition was completed, a heat map was
produced for iodine and gadolinium concentrations using the maxi-
mum concentration at the surface as the end point and the start point
as the first value below 5mg/ml of iodine or gadolinium adjacent to
the bone. The inverse relationship to GAG was based on a linear rela-
tionship determined in healthy bovine samples and overlaid on the
human OA cartilage images for proof of concept as zonal DMMB
layer analysis is not practical in non-healthy OA tissue due to its vary-
ing thickness, significantly reduced GAG content, and etiology related
damage and superficial layer erosion.
Histology
After the 24h washout period was complete, strips of approxi-
mately 5mm width were cut from the sample blocks. These strips
were then divided into two parts (approximately 22mm in length) to
be used for histological staining. These strips were decalcified in a solu-
tion of EDTA, pH 7.0, for a period of five weeks. After this period, the
samples were rinsed with PBS and dehydrated in an ethanol series
ranging from 70 to 100% in five steps.25 The samples were embedded
in paraffin wax, sectioned (5lm slices), and stained with Safranin O/
fast green/hematoxylin as described above.
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